Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Ross Moat Sells 2,367 Shares of Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Ross Moat sold 2,367 shares of the business’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $48.58, for a total value of $114,988.86. Following the transaction, the chief operating officer directly owned 12,029 shares of the company’s stock, valued at $584,368.82. This trade represents a 16.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Stock Performance

Shares of KNSA opened at $47.03 on Thursday. Kiniksa Pharmaceuticals International, plc has a 52 week low of $18.25 and a 52 week high of $50.03. The stock has a market capitalization of $3.60 billion, a price-to-earnings ratio of 63.55 and a beta of 0.06. The stock has a fifty day moving average of $45.82 and a 200-day moving average of $42.16.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, February 24th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.12). Kiniksa Pharmaceuticals International had a net margin of 8.71% and a return on equity of 11.48%. The firm had revenue of $202.13 million during the quarter, compared to the consensus estimate of $200.86 million. During the same quarter in the previous year, the company posted ($0.12) earnings per share. The firm’s revenue was up 65.0% on a year-over-year basis. As a group, equities analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on KNSA. Wedbush upped their target price on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Wells Fargo & Company upped their target price on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Zacks Research raised Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. Wall Street Zen cut Kiniksa Pharmaceuticals International from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. Finally, Canaccord Genuity Group began coverage on Kiniksa Pharmaceuticals International in a report on Thursday, February 19th. They issued a “buy” rating and a $62.00 target price for the company. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, Kiniksa Pharmaceuticals International has a consensus rating of “Moderate Buy” and a consensus target price of $55.29.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Rubric Capital Management LP increased its stake in shares of Kiniksa Pharmaceuticals International by 2.3% in the third quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company’s stock valued at $155,320,000 after buying an additional 90,194 shares during the period. Vanguard Group Inc. increased its stake in shares of Kiniksa Pharmaceuticals International by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 3,112,937 shares of the company’s stock valued at $128,409,000 after buying an additional 49,802 shares during the period. Arrowstreet Capital Limited Partnership increased its stake in shares of Kiniksa Pharmaceuticals International by 45.3% in the third quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company’s stock valued at $41,481,000 after buying an additional 332,846 shares during the period. Qube Research & Technologies Ltd increased its stake in shares of Kiniksa Pharmaceuticals International by 277.8% in the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after buying an additional 653,236 shares during the period. Finally, Millennium Management LLC increased its stake in shares of Kiniksa Pharmaceuticals International by 8.7% in the first quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after buying an additional 67,452 shares during the period. Institutional investors and hedge funds own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.